What's Going On With Travere Therapeutics Stock?
Portfolio Pulse from Erica Kollmann
Travere Therapeutics, Inc. (NASDAQ:TVTX) stock is trading higher after announcing FDA regulatory updates. The company completed a successful pre-NDA meeting for Filspari and plans to submit an sNDA in Q1 2024 for full approval. However, the FDA indicated that Phase 3 Duplex study results for FSGS are insufficient for an sNDA submission. Citigroup upgraded the stock from Neutral to Buy with a price target increase from $7 to $10, while HC Wainwright reiterated a Buy rating with an $18 price target. TVTX shares rose 25% to $7.89.
December 05, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Travere Therapeutics' stock is experiencing a positive impact following FDA regulatory updates and analyst upgrades. The company's successful pre-NDA meeting for Filspari and plans for an sNDA submission in 2024 are seen as positive developments, despite the FDA's feedback on FSGS study results.
The stock's rise is directly related to the positive regulatory news regarding Filspari and the subsequent analyst upgrades, which are strong indicators of investor confidence and potential for short-term price appreciation. The FDA's feedback on the FSGS study is a minor setback but seems overshadowed by the positive news.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100